Flamel Technologies' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Flamel Technologies S.A. (FLML)

Q2 2012 Earnings Conference Call

July 26, 2012 08:30 ET

Executives

Mike Anderson – Chief Executive Officer

Sian Crouzet – Principal Financial Officer

Analysts

Matt Kaplan – Ladenburg Thalmann

David Moskowitz – Private Investor

Peter Butler – Glen Hill Investments

Presentation

Operator

Compare to:
Previous Statements by FLML
» Flamel Technologies' CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Flamel Technologies' CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Flamel Technologies's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Flamel Technologies CEO Discusses Q2 2011 Results - Earnings Call Transcript

Good morning, ladies and gentlemen and welcome to the Flamel Technologies’ Second Quarter 2012 Results Conference Call. After prepared remarks, we’ll be opening the call to a Q&A period. (Operator Instructions) As a reminder, this call is being recorded.

It is now my pleasure to turn the call over to Mike Anderson, CEO. Please go ahead sir.

Mike Anderson

Thank you, operator, and good morning, ladies and gentlemen. We appreciate very much your joining us today.

Before we begin, I’ll have to open with our usual forward-looking statement language, which is also included in last night’s press release. All statements made on this call about future events, results, performance, products under development, plans or objectives are forward-looking. Actual results may differ materially from these statements due to risks and uncertainties over which we have no control. We encourage our shareholders to review the risk and other disclosures set forth in our SEC filings, which are all publicly available.

It remains a period of transition and transformation for Flamel and I am happy to report that we continue to gain momentum during the past quarter, becoming a more vertically integrated pharmaceutical company, and therefore a company better able to control its own future, remains a key priority for us and we continue to believe it is our best opportunity for delivering sustainable growth and shareholder value. Partnering our world-class drug delivery platforms continues to be a key part of our strategy that our expanded commercialization capabilities are now allowing Flamel to offer even more value to shareholders as our internal projects advance towards commercialization.

1 2 3 Next › Last »